Pro–A-Type Natriuretic Peptide, Proadrenomedullin, and N-Terminal Pro–B-Type Natriuretic Peptide Used in a Multimarker Strategy in Primary Health Care in Risk Assessment of Patients With Symptoms of Heart Failure
1 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet2 unknown3 Graduate School of Health and Medical Sciences, Faculty of Health and Medical Sciences, Københavns Universitet4 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet5 Graduate School of Health and Medical Sciences, Faculty of Health and Medical Sciences, Københavns Universitet
Use of new biomarkers in the handling of heart failure patients has been advocated in the literature, but most often in hospital-based populations. Therefore, we wanted to evaluate whether plasma measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-A-type natriuretic peptide (MR-proANP), and midregional proadrenomedullin (MR-proADM), individually or combined, gives prognostic information regarding cardiovascular and all-cause mortality that could motivate use in elderly patients presenting with symptoms suggestive of heart failure in primary health care.
Journal of Cardiac Failure, 2013, Vol 19, Issue 1, p. 31-9
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Adrenomedullin; Aged; Aged, 80 and over; Biological Markers; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Natriuretic Peptide, Brain; Normal Distribution; Peptide Fragments; Primary Health Care; Proportional Hazards Models; Protein Precursors; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Sweden; Time Factors